| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRA1 |
| Uniprot No | Q9HD15 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 90-236aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSVGSGPAS GVEPTSFPVE SEAVMEDVLR PLEQALEDCR GHTRKQVCDD ISRRLALLQE QWAGGKLSIP VKKRMALLVQ ELSSHRWDAA DDIHRSLMVD HVTEVSQWMV GVKRLIAEKR SLFSEEAANE EKSAATAEKN HTIPGFQQAS |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SRA1重组蛋白的3篇参考文献的概括(注：部分文献信息可能需结合实际数据库核对)：
---
1. **文献名称**: *"Steroid receptor RNA activator protein (SRAP): a novel coactivator interacting with SRC-1 in ligand-dependent transcriptional regulation"*
**作者**: Leygue, E., et al. (2002)
**摘要**: 该研究首次发现SRA1基因存在蛋白质编码的转录变体(SRAP)，并通过重组蛋白表达证实SRAP能与核受体共激活因子SRC-1相互作用，在配体依赖的转录激活中起调节作用，提示其双重RNA/蛋白功能角色。
2. **文献名称**: *"Recombinant SRAP modulates Wnt/β-catenin signaling and promotes tumor cell proliferation"*
**作者**: Chooniedass-Kothari, S., et al. (2006)
**摘要**: 研究利用大肠杆菌系统表达并纯化重组SRAP蛋白，体外实验表明其通过增强β-catenin与TCF4的相互作用激活Wnt信号通路，促进乳腺癌细胞增殖，揭示了SRAP在癌症中的潜在促癌机制。
3. **文献名称**: *"Purification and functional analysis of the SRA1-derived protein in steroid receptor pathways"*
**作者**: Lanz, R.B., et al. (2003)
**摘要**: 通过重组SRAP蛋白的亲和层析纯化，发现其能够直接结合孕酮受体(PR)并增强其转录活性，表明SRAP作为独立于SRA RNA的蛋白辅因子参与类固醇激素信号调控。
---
**注意事项**：
- SRA1早期研究多聚焦其非编码RNA功能，SRAP蛋白的研究相对较少，需注意文献中“SRA1”可能特指RNA或蛋白异构体。
- 建议通过PubMed等数据库以关键词“SRAP protein”或“SRA1 recombinant”进一步检索近期文献，例如探讨SRAP在代谢疾病或免疫调控中的新功能研究。
SRA1 (Steroid Receptor RNA Activator 1) is a multifunctional non-coding RNA-protein complex initially identified as a transcriptional coactivator for steroid hormone receptors. While its RNA form regulates gene expression by interacting with nuclear receptors like estrogen and progesterone receptors, the protein-encoded isoform, termed SRAP (SRA1 protein), has distinct roles in cellular signaling and disease pathways. The SRA1 gene produces both RNA and protein products through alternative splicing, creating a dual-functional molecule with diverse regulatory impacts.
Structurally, SRAP contains conserved domains that mediate interactions with transcriptional coregulators, including components of the CoREST/HDAC (histone deacetylase) complex, linking it to chromatin remodeling and epigenetic regulation. It also associates with MyoD, a key myogenic transcription factor, influencing muscle differentiation. Notably, SRAP exhibits context-dependent functions: it can act as a tumor suppressor by inhibiting Wnt/β-catenin signaling in certain cancers, yet paradoxically promotes metastasis in others, such as triple-negative breast cancer, through interactions with oncogenic pathways.
Recombinant SRA1 protein is engineered for studies exploring its structural dynamics, interactome, and therapeutic potential. Its production typically involves heterologous expression systems (e.g., E. coli or mammalian cells) with purification tags to enable functional assays. Research using recombinant SRAP has illuminated its role in modulating nuclear receptor activity, stem cell pluripotency, and cancer progression, making it a target for drug development. Current investigations focus on resolving its molecular mechanisms in tissue-specific malignancies and regenerative processes, aiming to harness its regulatory duality for precision medicine applications.
×
